Resources from the same session
853O - OMITting frontline chemotherapy in head and neck cancer (HNSCC) patients with 1-3 oligometastases using stereotactic ablative radiotherapy (SABR), the GORTEC 2014-04 “OMET” randomized phase II trial
Presenter: Juliette Thariat
Session: Proffered Paper session - Head and neck cancer
Resources:
Abstract
Slides
Webcast
857O - MACH-EGFR: Individual patient data (IPD) meta-analysis of anti-EGFR monoclonal antibodies (Ab) in patients (pts) with locally advanced (LA) squamous cell carcinomas of head and neck (SCCHN)
Presenter: Pierre Blanchard
Session: Proffered Paper session - Head and neck cancer
Resources:
Abstract
Slides
Webcast
Invited Discussant 853O and 857O
Presenter: Silke Tribius
Session: Proffered Paper session - Head and neck cancer
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session - Head and neck cancer
Resources:
Webcast
858O - Minimal residual disease (MRD) diagnosed by a plasma tumor-agnostic circulating tumor DNA (ctDNA) assay after curative therapy in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN) predicts disease relapse and survival
Presenter: Natasha Honoré
Session: Proffered Paper session - Head and neck cancer
Resources:
Abstract
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session - Head and neck cancer
Resources:
Webcast
854O - INTERLINK-1: Phase III study of cetuximab (CTX) ± monalizumab (M) in participants (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) with disease progression on/after platinum chemotherapy (CT) and previously treated with an immune checkpoint inhibitor (ICI)
Presenter: Jérome Fayette
Session: Proffered Paper session - Head and neck cancer
Resources:
Abstract
Slides
Webcast
Invited Discussant 854MO
Presenter: Christophe Le Tourneau
Session: Proffered Paper session - Head and neck cancer
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session - Head and neck cancer
Resources:
Webcast